Trojan mast cells: repurposing allergy for targeted oncolytic delivery.

Oncolytic viruses hold immense therapeutic promise but face formidable systemic delivery barriers. A new study by Xu et al. engineered immunoglobulin E-sensitized mast cells to selectively ferry these viruses into tumors. Excitingly, antigen-triggered degranulation precisely releases the viral payload and reshapes the immune microenvironment, offering a highly modular delivery paradigm.